Healthcare

Abu Dhabi partners deploy AI to accelerate clinical trials

Oracle, AstraZeneca and M42 are using AI in Abu Dhabi to identify patients with uncontrolled hypertension and improve clinical-trial recruitment. M42 also launched an AI platform expected to increase clinicians’ time with patients.

Oracle, AstraZeneca and M42 partnered to use artificial intelligence to accelerate clinical trials and improve patient matching in Abu Dhabi. The initial program focuses on hypertension care and research, with clinical teams identifying patients whose blood pressure is uncontrolled and supporting recruitment into relevant trials. The program is intended to help care teams implement treatment while generating a more efficient pathway for research participation. The partners expect to assess early results within about a year, including whether the approach improves trial participation and helps identify suitable trial sites. The initiative illustrates how clinical data and AI can connect routine care with research operations. It also forms part of Abu Dhabi’s broader effort to develop the emirate as a center for clinical trials. Separately, M42 launched Ossi, an AI platform developed with Microsoft, which is expected to give doctors more time with patients. Ossi is planned for deployment across seven M42 centers in the UAE and Bahrain. Together, the projects show practical applications of AI in patient identification, clinical research recruitment and workflow automation. For healthcare providers, the potential value lies in reducing manual screening and improving access to trials for patients with specific conditions.

Original source: The National

Related RAQI solutions

In-depth analysis on RAQI Insight

Work with RAQI